Clinical Trials Logo
  1. Home
  2. Major Depression
  3. NCT00343070
  4. Details
NCT00343070 Clinical Trial

Functional Neuroimaging in Depression

Major Depression Clinical Trial

Official title:
Functional Neuroimaging in Depression: Longitudinal Study of PET Metabolism in Correlation With Changes in Attentional Bias, Autobiographical Memory, Future Fluency and Facial Recognition in Depressed Patients Treated With Escitalopram.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00343070
Other study ID # 2006/176
Secondary ID
Status Completed
Phase Phase 2
First received June 19, 2006
Last updated August 30, 2010
Start date March 2007
Est. completion date October 2009

Study information
Verified date August 2010
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicines and Health Products, FAMHP
Study type Interventional

Clinical Trial Summary

Oral administration of escitalopram during 8 weeks; PET scan with 18F-FDG at inclusion and after 8 weeks

Recruitment information / eligibility
Status Completed
Enrollment 40
Est. completion date October 2009
Est. primary completion date October 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Major Depression, Depressive episode, following DSM-IV criteria

- MADRS-score > 25

- Age: 18-65 yrs

- Medication-free or anti-depressant wash-out 7 days (for fluoxetine: 6 weeks)

- Lorazepam 1mg or zolpidem 10mg are allowed

Exclusion Criteria:

- Suicidality

- Bipolar disorder, following DSM-IV criteria

- Psychotic symptoms

- Substance abuse

- Personality disorder, following DSM-IV criteria

- Cognitive dysfunction due to trauma capitis or dementia

- Diabetes mellitus

- Women without contraceptive protection, with pregnancy or breast feeding

- Pharmacological treatment or ingestion of substance that can influence cerebral perfusion less than a month before inclusion

- IQ below 80

- Conditions not compatible with SPC

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Oral administration of escitalopram during 8 weeks

Locations
Country Name City State
Belgium University Hospital Ghent Ghent
Belgium AZ Groeninge campus Sint Maarten Kortrijk

Sponsors (3)
Lead Sponsor Collaborator
University Hospital, Ghent Fund for Scientific Research, Flanders, Belgium, H. Lundbeck A/S

Country where clinical trial is conducted

Belgium, 

Outcome
Type Measure Description Time frame Safety issue
Primary Brain metabolism
Secondary Cognitive functions
Secondary Efficacy scales (mood, anxiety, anger and hopelessness)
See also
  Status Clinical Trial Phase
Completed NCT03062150 - Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression N/A
Completed NCT04352101 - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits Phase 4
Completed NCT02855918 - Blood Biomarkers in Suicidal Behaviour N/A
Recruiting NCT03039387 - Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients N/A
Recruiting NCT02213016 - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Phase 4
Completed NCT01683539 - Understanding How Cognitive Remediation Works N/A
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3
Recruiting NCT02237937 - Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Phase 4
Completed NCT01201148 - Open Pilot Trial of TES for Depression Phase 2
Completed NCT00953108 - Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients Phase 3
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00806143 - Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression Phase 4
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Terminated NCT00695552 - The Effect of Exercise on Depressive Symptoms in Unmedicated Patients N/A
Completed NCT00482482 - Yoga in Unipolar and Bipolar Disorders N/A
Completed NCT00466323 - The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness. N/A
Completed NCT00532480 - Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine Phase 4
Completed NCT00616759 - The Effect on Cognition of Terminating ECT Induced Seizures With Propofol N/A
Recruiting NCT00209807 - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Phase 4
Completed NCT00167310 - Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation Phase 2

External Links